Melanotan I

Wellness

Also known as: Afamelanotide, Scenesse, NDP-MSH, [Nle4, D-Phe7]-α-MSH, MT-I, MT1

Well-Studied

What is Melanotan I?

A linear synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the early 1980s and later brought to market by Clinuvel as afamelanotide (brand name Scenesse). This is the rare case of a "biohacking" peptide with a genuine FDA approval (2019) and EMA approval (2014) — but only for a specific rare disease, erythropoietic protoporphyria (EPP), delivered as a controlled-release subcutaneous implant. It is also the molecule most confused with Melanotan II: gray-market "Melanotan" sold for tanning is almost always the cyclic, non-selective MT-II, not this one.

How it works

Binds the melanocortin-1 receptor (MC1R) on melanocytes, stimulating eumelanin production and skin darkening independent of UV exposure. The key pharmacological difference from Melanotan II is selectivity: Melanotan I is a linear peptide that acts predominantly on MC1R, while Melanotan II is a cyclic, non-selective agonist that also strongly activates MC3R and MC4R in the brain — the receptors responsible for MT-II's appetite suppression, sexual arousal, and much of its nausea and flushing. Because Melanotan I largely spares MC4R, it produces tanning with a comparatively cleaner side-effect profile and without the libido/erection effects MT-II is known for. In its approved clinical use, a 16 mg afamelanotide implant is inserted above the anterior supra-iliac crest and releases the peptide over roughly two months, a very different exposure pattern from the daily or every-other-day self-injected powder that gray-market "Melanotan" users typically take.

What marketers claim

▸a safer, "cleaner" alternative to Melanotan II for tanning
▸gives a deep, UV-free base tan with no libido or nausea side effects
▸the same thing as the Melanotan II sold online, just milder
▸provides meaningful sunburn protection

What evidence supports

✓FDA-approved (October 2019) as Scenesse, an implant that increases pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)
✓EMA-approved (2014) as the first treatment for prevention of phototoxicity in EPP, under exceptional circumstances given the rarity of the disease
✓two pivotal randomized, double-blind, placebo-controlled trials (EU and US, 168 patients combined) showed afamelanotide implants significantly increased hours of pain-free direct sunlight exposure and improved quality of life compared with placebo
✓an early randomized, placebo-controlled trial in 28 healthy men (Levine et al., 1991) demonstrated that subcutaneous [Nle4, D-Phe7]-α-MSH induces skin tanning without UV exposure — the original proof-of-concept for melanotropin-driven pigmentation
✓because it is more MC1R-selective than Melanotan II, it does not reliably produce the appetite-suppressing or erectogenic effects seen with MT-II

Research evidence

Key studies on Melanotan I, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.

Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin

1991Randomized Controlled Trialn = 28 healthy men

Finding: Subcutaneous injection of [Nle4, D-Phe7]-α-MSH (the compound later developed as afamelanotide/Melanotan I) induced measurable skin darkening independent of UV exposure, in both poor-tanning and good-tanning skin types.

Limitation: Small, short-duration study in healthy volunteers using a daily injection protocol quite different from the later-approved bimonthly implant; not designed to assess long-term safety.

Afamelanotide for Erythropoietic Protoporphyria

2015Randomized Controlled Trialn = 168 patients (two trials: 74 in the EU, 94 in the US)

Finding: Randomized, double-blind, placebo-controlled implant trials found afamelanotide significantly increased hours of direct, pain-free sunlight exposure and improved quality of life in EPP patients compared with placebo, forming the basis for EMA and later FDA approval.

Limitation: Conducted in a rare-disease population using a specific 16 mg implant dosed every 60 days under clinical supervision — results do not generalize to self-administered dosing for cosmetic tanning in the general population.

Best for

understanding as an approved orphan drug for EPP — not recommended for self-directed cosmetic tanning use

What to expect

Realistic timeline based on available research. Individual results vary.

Approved EPP use (implant)

A 16 mg afamelanotide implant is inserted subcutaneously by a clinician roughly every two months. In trials, this schedule increased the number of hours patients could tolerate direct sunlight without phototoxic pain over a 6-9 month treatment period.

Early tanning studies (historical)

In the 1991 Levine et al. trial, daily subcutaneous injections over about two weeks produced visible, UV-independent skin darkening in healthy volunteers, establishing the original concept behind melanotropin-based tanning.

Gray-market self-use (unstudied)

Self-injection protocols circulating online are not derived from any published dosing trial and are not comparable to either the approved implant or the historical research studies. No safety or efficacy data exists for these regimens.

Safety notes & concerns

Full safety guide →

⚠the biggest source of confusion: most "Melanotan" sold online for tanning is actually Melanotan II, mislabeled or informally shortened to "Melanotan" — buyers often cannot verify which peptide, or what purity, is actually in the vial
⚠the FDA/EMA-approved use is a clinician-administered 16 mg implant dosed once every ~2 months for a specific rare disease — this bears little resemblance to self-injecting research-grade powder for cosmetic tanning, and no clinical safety data covers that use pattern or dose
⚠even in its approved EPP indication, afamelanotide requires enrollment in a monitoring program with periodic full-body skin and mole examinations, reflecting ongoing vigilance around melanocortin agonists and pigmented lesions
⚠self-sourced peptides marketed as "Melanotan I" are unregulated — contamination, incorrect concentration, and outright mislabeling as MT-II are documented problems in gray-market peptide sales
⚠darkening or changes in existing moles and nevi have been reported with melanocortin agonists generally; anyone with atypical moles or a personal/family melanoma history should not self-experiment with either Melanotan compound
⚠increased melanin is not a substitute for sunscreen — tanning from MC1R activation does not confer the UV protection of an actual SPF barrier, and the approved EPP trials measured pain-free light tolerance in a disease population, not sunburn prevention in healthy skin

Pairs well with

sunscreen (UV protection remains essential regardless of melanin levels)

Use caution with

history of melanoma, atypical/dysplastic moles, or a strong family history of melanomapregnancyself-sourced injectable peptides of unverified identity and purityassuming it is a "safe" substitute for Melanotan II without the same sourcing and monitoring concerns

Frequently asked questions

Is Melanotan I the same as Melanotan II?

No, and this is the single most important distinction to understand. Melanotan I (afamelanotide) is a linear peptide that acts mainly on MC1R and is FDA/EMA-approved as Scenesse for the rare disease erythropoietic protoporphyria. Melanotan II is a cyclic peptide that non-selectively activates multiple melanocortin receptors, including MC4R, giving it more pronounced effects on libido and appetite along with more side effects. Despite the name similarity, they are different molecules with different regulatory status, and most gray-market "Melanotan" for tanning is actually MT-II.

Is Melanotan I approved for tanning?

No. Afamelanotide (Scenesse) is approved by the FDA and EMA for a single narrow indication — increasing pain-free light exposure in adults with erythropoietic protoporphyria — administered as a clinician-placed implant. It is not approved anywhere as a cosmetic tanning agent, and no regulatory body has evaluated self-injected Melanotan I for that use.

Is Melanotan I safer than Melanotan II?

Its receptor selectivity means it is less likely to cause the nausea, flushing, and spontaneous erections associated with Melanotan II's MC4R activity, and it has an actual regulatory approval and clinical trial record behind it — unlike MT-II. But "safer than MT-II" is not the same as "safe to self-inject for tanning." The approved use is a monitored, clinician-administered implant at a specific dose and schedule; self-sourced injectable powder carries the same sourcing, purity, and mole-monitoring concerns that apply to MT-II.

Does Melanotan I protect against sunburn?

The clinical trials measured pain-free light tolerance in EPP patients, a very different endpoint from sunburn prevention in the general population. Increased melanin provides some UV absorption, but it is not equivalent to sunscreen, and relying on it in place of SPF protection is not supported by the approval data.